Literature DB >> 24939719

Denosumab for management of refractory hypercalcaemia in recurrent parathyroid carcinoma.

K Nadarasa1, A Theodoraki1, T R Kurzawinski1, R Carpenter1, J Bull1, T T Chung1, W M Drake2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24939719     DOI： 10.1530/EJE-14-0482

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN： 0804-4643            Impact factor:   6.664


× No keyword cloud information.
  3 in total

Review 1.  Management of endocrine disease: Secondary osteoporosis: pathophysiology and management.

Authors:  Faryal Mirza; Ernesto Canalis
Journal:  Eur J Endocrinol       Date:  2015-05-13       Impact factor: 6.664

2.  Pitfalls of using denosumab preoperatively to treat refractory severe hypercalcaemia.

Authors:  Yulong Li; Chris Y Fan; Andrea Manni; William F Simonds
Journal:  BMJ Case Rep       Date:  2020-04-28

Review 3.  Denosumab for the Treatment of Hypercalcemia in a Patient With Parathyroid Carcinoma: A Case Report.

Authors:  Abdallah Roukain; Heba Alwan; Massimo Bongiovanni; Gerasimos P Sykiotis; Peter A Kopp
Journal:  Front Endocrinol (Lausanne)       Date:  2022-01-31       Impact factor: 5.555
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.